Skip to main content
. 2024 Feb 5;6(2):290–303. doi: 10.1038/s42255-023-00966-w

Fig. 1. AMG 133 exhibited GIPR antagonist and GLP-1R agonist activities in vitro and extended PK profiles.

Fig. 1

a, Structure of AMG 133. The GLP-1 analogue peptide sequence is H[Aib]EGTFTSDYSSYLEEQAAKEFIAWLVKGGG(GGGGS)3 K(BrAc){CONH2}. b, In vitro potency of AMG 133. c–e, PK properties after a single dose of 5 mg kg−1 i.v. administration of AMG 133 to CD-1 mice (c), a single dose of 3 mg kg−1 s.c. administration of AMG 133 to female cynomolgus monkeys (d) and s.c. administration of AMG 133 to obese male cynomolgus monkeys (e). AUC, area under the curve; AUCinf, AUC zero to infinity; Vss, volume in steady state; CL, clearance; F, fraction absorbed; EC50, half maximal effective concentration; GIPR, glucose-dependent insulinotropic polypeptide receptor; GLP-1R, glucagon-like peptide-1 receptor; IC50, half maximal inhibitory concentration; IV, intravenous; PK, pharmacokinetic; SC, subcutaneous; tmax, time of maximum observed concentration.